quinoline-5-carbonyl chloride | 441004-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: quinoline-5-carbonyl chloride
• 英文别名: 5-quinolinecarbonyl chloride
• CAS: 441004-94-0
• 化学式: C₁₀H₆ClNO
• 分子量: 191.617
• InChiKey: XNEVJLJCAPXMSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  quinoline-5-carbonyl chloride 在 劳森试剂 、 sodium hydroxide 作用下， 以 丙酮 、 甲苯 为溶剂， 反应 6.0h， 生成 [Methyl-(quinoline-5-carbothioyl)-amino]-acetic acid ethyl ester
  参考文献：
  名称：

  Synthesis and aldose reductase inhibitory activity of N-(quinolinyl thiocarbonyl) glycine derivatives

  摘要：

  The onset of diabetic complications may be prevented by the inhibition of aldose reductase. Derivatives of N-(quinolinyl thiocarbonyl) glycine were prepared and their in vitro and ex vivo aldose reductase inhibitory activities were tested on rat lens. The cincophen derivatives were the most potent in vitro with an enzyme inhibition value of 29% at 10(-8) M and 91% at 10(-7) M for the N-[(2-phenylquinolin-4-yl)thiocarbonyl]-N-methylglycine compound 10a This activity was shown to be dependent on the nature of the substituents and seems to be optimal for the acids; esters were found to be inactive. No compound have shown ex vivo inhibitory activity. It is concluded that the lack of ex vivo activity is likely due to a poor bioavailability or a bad penetration of the compounds in target tissue (lens).

  DOI：

  10.1016/0223-5234(92)90032-v
• 作为产物：
  描述：

  喹啉-5-羧酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 生成 quinoline-5-carbonyl chloride
  参考文献：
  名称：

  一系列新型的取代的1-苄基-5-苯基四唑P2X7拮抗剂的结构活性关系研究。

  摘要：

  发现1-苄基-5-芳基四唑是P2X（7）受体的新型拮抗剂。围绕苄基和苯基部分进行了结构-活性关系（SAR）研究。另外，检查了在四唑上区域化学取代的重要性。使用荧光成像酶标仪技术评估了化合物在人和大鼠重组P2X（7）细胞系中抑制钙通量的活性。还分析了类似物在人THP-1细胞中抑制IL-1β释放和抑制P2X（7）介导的孔形成的能力。化合物15d已在神经性疼痛模型中进行了功效研究，在该模型中，在不影响运动协调的剂量下观察到了机械性异常性疼痛的明显逆转。

  DOI：

  10.1021/jm051202e

文献信息

• NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Florjancic S. Alan

  公开号：US20080058335A1

  公开（公告）日：2008-03-06

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1 , R 2 , R 3 , and L 1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R 1a , R 2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1 ，R 2 ，R 3 和L 1 在规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物， 其中R 1a ，R 2a 和(Rx)n如规范中定义，包含这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• [EN] NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF<br/>[FR] NOUVEAUX COMPOSÉS EN TANT QUE LIGANDS DE RÉCEPTEUR DE CANNABINOÏDE ET LEURS UTILISATIONS
  申请人：ABBOTT LAB

  公开号：WO2009067613A1

  公开（公告）日：2009-05-28

  The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (I). wherein R1, R2, R3, R4, and L1 are defined in the specfication, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, formula (II). wherein R1a, R2a, Rx, and n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

  本发明涉及式(I)的化合物，或药用盐、前药、前药的盐或其组合物，式(I)。其中R1、R2、R3、R4和L1在规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。本发明还涉及式(II)的化合物，或药用盐、前药、前药的盐或其组合物，式(II)。其中R1a、R2a、Rx和n如规范中定义，包括含有这种化合物的组合物，以及使用这种化合物和组合物治疗疾病和疾病的方法。
• Oxidative C−H/C−H Cross-Coupling Reactions between <i>N</i> -Acylanilines and Benzamides Enabled by a Cp*-Free RhCl₃ /TFA Catalytic System
  作者：Yang Shi、Luoqiang Zhang、Jingbo Lan、Min Zhang、Fulin Zhou、Wenlong Wei、Jingsong You

  DOI：10.1002/anie.201804528

  日期：2018.7.16

  oxidative C−H/C−H cross‐coupling reaction between an N‐acylaniline and a benzamide has been accomplished for the first time. This process constitutes a step‐economic and highly efficient pathway to 2‐amino‐2′‐carboxybiaryl scaffolds from readily available substrates. A Cp*‐free RhCl3/TFA catalytic system was developed to replace the [Cp*RhCl2]2/AgSbF6 system generally used in oxidative C−H/C−H cross‐coupling

  通过使用双重螯合辅助策略，首次实现了N-丙氨酸与苯甲酰胺之间完全区域控制的氧化CH / C-H交叉偶联反应。此过程构成了从容易获得的底物制备2-氨基2'-羧基联芳基支架的经济高效的步骤。开发了无Cp *的RhCl 3 / TFA催化体系来代替通常用于两个（杂）芳烃（Cp）的氧化CH / CH交叉偶联反应中的[Cp * RhCl 2 ] 2 / AgSbF 6体系* ＝五甲基环戊二烯基，TFA ＝三氟乙酸）。RhCl 3 / TFA系统避免使用昂贵的Cp *配体和AgSbF 6。作为说明性实例，本文开发的方法极大地简化了天然存在的苯并[ c ]菲啶生物碱氧基亚硝胺的总合成，这以优异的总收率实现。
• Structure-activity relationships and antiproliferative effects of 1,2,3,4-4H-quinoxaline derivatives as tubulin polymerization inhibitors
  作者：Tingting Liang、Xiaomin Zhou、Lu Lu、Haiyang Dong、Yanan Zhang、Yungen Xu、Jianguo Qi、Yahong Zhang、Jianhong Wang

  DOI：10.1016/j.bioorg.2021.104793

  日期：2021.5

  cancer cell lines, and most of the target compounds demonstrated moderate to strong activities towards two tumor cell lines. In addition, the structure-activity relationships of these derivatives were also discussed. Among them, compounds 11a and 11b showed the most potent activities. Moreover, compound 11a inhibited the tubulin polymerization in both cell-free and cellular assays. Further profiling of compound

  秋水仙碱结合位点抑制剂（CBSI）在治疗各种肿瘤方面具有巨大潜力，它们可以克服现有微管蛋白抑制剂如紫杉醇和长春瑞滨面临的多药耐药性。在此，我们报告了一系列作为秋水仙碱结合位点抑制剂的四氢喹喔啉衍生物的设计、合成和生物学评价。评估了所有合成的化合物对 HT-29 和 Hela 癌细胞系的体外抗增殖活性，大多数目标化合物对两种肿瘤细胞系表现出中等至强的活性。此外，还讨论了这些衍生物的构效关系。其中，化合物11a和11b表现出最有力的活动。此外，化合物11a在无细胞和细胞试验中均抑制微管蛋白聚合。化合物11a 的进一步分析表明，它在 G2/M 期阻止细胞周期并以剂量依赖性方式诱导细胞凋亡。此外，分子对接研究证明化合物11a作用于秋水仙碱结合位点。因此，11a是发现秋水仙碱结合位点抑制剂的有希望的候选物。
• Chemistry of ecteinascidins. Part 3: Preparation of 2′-N-acyl derivatives of ecteinascidin 770 and evaluation of cytotoxicity
  作者：Panithi Saktrakulkla、Satoru Toriumi、Mitsuhiro Tsujimoto、Chamnan Patarapanich、Khanit Suwanborirux、Naoki Saito

  DOI：10.1016/j.bmc.2011.06.047

  日期：2011.8

  2′-N-indole-3-carbonyl derivative 3 via 18,6′-O-bisallyl-protected derivative 4a, which was shown to have higher cytotoxicity than 1b, is presented. In addition, a number of 2′-N amide derivatives of 1b have been prepared from 4a and their in vitro cytotoxicity were determined by measuring IC50 values against human cell lines HCT116, QG56, and DU145. Benzoyl amide derivatives 7a–c showed similar in

  海鞘素770（的三步变换1b中）转换成2'- ñ -吲哚-3-羰基衍生物3经由18,6'- Ô -bisallyl保护的衍生物4a中，其显示出具有高于细胞毒性1B，呈现。此外，从4a制备了许多1b的2'- N酰胺衍生物，并通过测量针对人细胞系HCT116，QG56和DU145的IC 50值来确定其体外细胞毒性。苯甲酰胺衍生物7a – c显示出与1b相似的体外细胞毒性，而含氮杂环衍生物7d – h和肉桂酰基衍生物9a – b显示出比1b高的细胞毒性。相比之下，相对于1b，由18,6'- O-双烯丙基保护的衍生物4a – c，6a – h和8a – b显示出明显的细胞毒性降低。